Rentschler Biopharma expands U.S. footprint

by Biotech Newsroom


EuroBiotech_What specific expertise does Rentschler Biopharma have in the development and production of bispecific antibodies?

Pollano_At Rentschler Biopharma, our strength lies in our proficiency with highly complex molecules. Our track record of 100 therapeutic protein formats, for a total of about 300 molecules, clearly reflects this expertise. We have almost 20 years of experience in the production of multispecific antibodies, including bispecific and trispecific antibodies. These account for close to one quarter of our development and production portfolio. This is no small feat, and we pride ourselves on the know-how and capabilities that we…



Source link

You may also like

Houston, TX – (EmailWire) — The Biotech Times™ aggregates, publishes and distributes news about the Biotech Industry. In association with EmailWire™, The Biotech Times, helps businesses and organizations in the industry with press release distribution. Press releases are disseminated to journalists, experts, investors, trade publications and other related media outlets. For more information, contact us through the following messaging apps:

Free Magazines

Recent Articles

BioTech Times™ is part of GroupWeb Media Network. © 2026 GroupWeb Media LLC